Evaluation of the ctDNA LUNAR Test in an Average Patient Screening Episode (ECLIPSE)
Associated condition: Colorectal cancer
Status: Currently enrolling
Brief summary: This is a prospective, observational multi-site study without randomization to assess the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population of participants ranging in age from 65 years to 84 years. An estimated 10,000 participants would undergo a blood draw for ctDNA LUNAR-2 testing prior to colonoscopy.
Primary objectives: To assess the performance characteristics of a blood-based ctDNA LUNAR-2 test to detect colorectal cancer in a screen-relevant, average risk population who would normally undergo invasive colonoscopy.
Estimated length of study: The Estimated Study Completion Date is January 1, 2024
For more detailed information on this research trial, including eligibility and study design, please visit the clinical trial page at U.S. National Library of Medicine’s website. Note you can submit your information for consideration by submitting the contact form on this page.
